Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced on September 7, 2026 that...
Drug
Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
Hualan Biological Engineering Inc. (SHE: 002007) announced on September 8, 2026 that its novel influenza...
NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
MediLink Therapeutics announced that the New Drug Application (NDA) for Tam‑Peli (tamatanmab pelidotin for injection;...
Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Santen Pharmaceutical (TYO: 4536) announced that the New Drug Application (NDA) for its atropine sulfate...
TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb
TenNor Therapeutics (HKG: 6872) today announced positive top‑line results from its Phase IIa proof‑of‑concept clinical...
MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has...
Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug,...
Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China’s...
Yipinhong’s AR882 Meets Primary Endpoint in Phase 3 Gout Trial, Outperforming Febuxostat on Uric Acid Reduction
Yipinhong Pharmacy Group Co., Ltd (SHE: 300723) announced that its Phase 3 trial for the...
AbbVie’s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig,...
Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress
Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical...
NMPA Approves Eisai’s Lecanemab Subcutaneous Autoinjector for Early Alzheimer’s Disease in China
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that China’s National Medical...
Kanghong’s Conbercept Wins NMPA Approval for Fifth Indication in Retinopathy of Prematurity (ROP)
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that China’s National Medical Products Administration...
Simcere’s Culevibart Wins NMPA Approval as China’s RSV Prevention Monoclonal Antibody Yingmule
Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category...
Sino Biopharmaceutical’s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors
Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed...
Fosun Pharma’s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib...
Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a...
Hengrui’s drotokibart BLA Accepted by NMPA for Moderate-to-Severe Atopic Dermatitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the National Medical Products...
GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate
Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational...
Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its New Drug Application...